Topiramate for the treatment of juvenile myoclonic epilepsy

Arquivos de Neuro-Psiquiatria

Patrícia Da Silva Sousa¹  Gerardo Maria De Araújo Filho¹  Eliana Garzon¹  Américo C. Sakamoto¹  Elza Márcia T. Yacubian¹ 

[1] ,Universidade Federal de São Paulo Escola Paulista de Medicina Unidade de Pesquisa e Tratamento das EpilepsiasSão Paulo SP ,Brazil

关键词: topiramate;    treatment;    juvenile myoclonic epilepsy;    topiramato;    tratamento;    epilepsia mioclônica juvenil;   

DOI  :  10.1590/S0004-282X2005000500001

来源: SciELO

【 摘 要 】

OBJECTIVE: The aim of this study was to evaluate the efficacy and tolerability of topiramate (TPM) in juvenile myoclonic epilepsy (JME). METHOD: We assessed seizure control and adverse effects of TPM in 22 patients (18 females) aged 13 to 53 years. Target TPM dosage was up to 200 mg/day. The patients were subdivided into 3 groups: those treated with seizure control plus side effects (n=4); treated with non-controlled seizures (n=15) and with JME newly diagnosed (n=3). RESULTS: Sixteen patients completed the first year of the follow-up. Generalized tonic-clonic seizures were completely controlled in 10 (62.5%); more than 50% of reduction in 4 (25.0%) and less than 50% in 2 (12.5%). Myoclonia were controlled in 11 (68.8%) and persisted in 5 (31.2%) patients. Absence seizures were present in 5 (22.7%) of whom 2 (9.0%) showed more than 50% of seizure reduction while 3 (13.6%) presented worsening. Discontinuations were due to inadequate seizure control and adverse events (N=4), low compliance and loss of follow-up (N=2) and subject choice (N=1). CONCLUSION: TPM showed to be an effective and well-tolerated drug in the treatment of JME. Although frequently observed, TPM side effects were tolerable and the drug could be maintained in the majority of patients.

【 授权许可】

CC BY   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License